# EU-1-11-668_public-assessment-report_20110311_20180206_daliresp-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH
Assessment report for
Daliresp
International Nonproprietary Name: roflumilast
Procedure No. EMEA/H/C/002398
Assessment Report as adopted by the CHMP with all inform
deleted.
ation of a commercially confidential nature
Medicinal product no Yorager authorised
7 Westferry Circus . Canary Wharf . London E14 4HB . United Kingdom
Telephone +44 (0)20 7418 8400 Facsimile +44 (0)20 7418 8613
E-mail info@ema.europa.eu Website www.ema.europa.eu
An agency of the European Union
C European Medicines Agency, 2011. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
4
4
1.1. Submission of the dossier.
1.2. Steps taken for the assessment of the product
4
2. Scientific discussion
5
2.1. Introduction
5
2.2. Quality aspects
5
2.3. Non-clinical aspects
5
6
2.4. Clinical aspects
6
2.5. Pharmacovigilance.
12
2.6. Recommendation
Medicinal product no longer authorised
EMA/43726/2011
2/12
